Ahmedabad: Torrent Pharmaceuticals Ltd reported a 9.6% year-on-year decline in consolidated net profit to Rs 534 crore for the second quarter of FY27, despite a 50.8% rise in revenue to Rs 4,979 crore.
Operating EBITDA rose 53.8% to Rs 1,666 crore, while the operating EBITDA margin improved to 33.5% from 32.8% a year earlier. The company’s revenue growth indicated the inclusion of the JB business and stronger performance in its core markets.
Torrent Pharma’s base business revenue grew 18% to Rs 3,893 crore, driven by branded formulations. India revenue rose 20% to Rs 2,181 crore, outpacing the Indian pharmaceutical market’s 12% growth, according to the PharmaTrac dataset cited by the company. The company reported a 32% market share for its generic semaglutide portfolio, combining oral and injectable products. The JB business recorded revenue of Rs 1,086 crore during the quarter.
Its integration following the merger, effective July 8, 2026, temporarily affected revenue. The company attributed the impact to integrating the India business, optimising its global business network, and aligning manufacturing and quality management systems. You Can Also Check: Gold Rate in Ahmedabad | Silver Rate in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad | Ahmedabad AQI | Weather in Ahmedabad | Petrol Price in Ahmedabad | Diesel Price in Ahmedabad | CNG Price in Ahmedabad | LPG Price in Ahmedabad